Waldron Private Wealth LLC Acquires 29 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Waldron Private Wealth LLC raised its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 1.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,681 shares of the company’s stock after purchasing an additional 29 shares during the period. Waldron Private Wealth LLC’s holdings in HCA Healthcare were worth $683,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Fisher Asset Management LLC bought a new stake in shares of HCA Healthcare during the fourth quarter valued at approximately $223,000. Global Assets Advisory LLC bought a new stake in shares of HCA Healthcare during the first quarter valued at approximately $5,505,000. Riverview Trust Co bought a new stake in shares of HCA Healthcare during the first quarter valued at approximately $58,000. Dynamic Advisor Solutions LLC increased its position in shares of HCA Healthcare by 3.0% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,405 shares of the company’s stock valued at $1,803,000 after acquiring an additional 156 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC bought a new stake in shares of HCA Healthcare during the first quarter valued at approximately $566,000. Institutional investors own 62.73% of the company’s stock.

Insider Transactions at HCA Healthcare

In related news, EVP Michael S. Cuffe sold 8,358 shares of HCA Healthcare stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the transaction, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Christopher F. Wyatt sold 4,000 shares of HCA Healthcare stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $360.20, for a total transaction of $1,440,800.00. Following the completion of the transaction, the senior vice president now directly owns 40,449 shares of the company’s stock, valued at approximately $14,569,729.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the sale, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,202 shares of company stock worth $6,407,273 in the last three months. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HCA shares. StockNews.com upgraded shares of HCA Healthcare from a “buy” rating to a “strong-buy” rating in a report on Monday, July 1st. Barclays raised their target price on shares of HCA Healthcare from $376.00 to $396.00 and gave the stock an “overweight” rating in a report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft raised their target price on shares of HCA Healthcare from $359.00 to $375.00 and gave the stock a “buy” rating in a report on Friday, June 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $392.00 price target on shares of HCA Healthcare in a research note on Tuesday, October 1st. Finally, UBS Group lifted their price target on shares of HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $367.15.

HCA Healthcare Stock Performance

Shares of NYSE HCA opened at $408.17 on Wednesday. The firm’s fifty day moving average is $393.95 and its two-hundred day moving average is $351.69. HCA Healthcare, Inc. has a 52-week low of $215.96 and a 52-week high of $417.14. The company has a debt-to-equity ratio of 27.11, a quick ratio of 0.94 and a current ratio of 1.06. The company has a market cap of $106.91 billion, a P/E ratio of 20.35, a P/E/G ratio of 1.44 and a beta of 1.67.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Tuesday, July 23rd. The company reported $5.50 earnings per share for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53. HCA Healthcare had a net margin of 8.40% and a return on equity of 553.13%. The firm had revenue of $17.49 billion for the quarter, compared to the consensus estimate of $17.05 billion. During the same period in the previous year, the firm posted $4.29 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, analysts anticipate that HCA Healthcare, Inc. will post 22.51 EPS for the current fiscal year.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.